Newsroom

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Latest News

Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

Tevogen Bio – June 30th, 2022


Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board

Tevogen Bio – June 23rd, 2022


Ryan Saadi’s Commencement Speech at Washington University of Science and Technology

Tevogen Bio – June 21st, 2022


Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

Tevogen Bio – June 7th, 2022


Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio

Tevogen Bio – May 3rd, 2022


Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness

Tevogen Bio – April 5th, 2022


Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board

Tevogen Bio – March 2nd, 2022


Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations

Tevogen Bio – February 7th, 2022


Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Tevogen Bio – February 3rd, 2022


SPH Dean’s next venture to drive down treatment costs

Yale Daily News – January 26th, 2022


Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

Tevogen Bio – January 20th, 2022


Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio – January 12th, 2022


Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council

Tevogen Bio – January 5th, 2022


Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19

Businesswire – December 29th, 2021


Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021

Businesswire – December 14th, 2021


Tevogen Bio Announces U.S. Patent and Trademark Office Has Granted Patent for Preparation of Tevogen’s SARS-CoV-2 Specific Allogeneic Cytotoxic T Lymphocytes (CTL) and Methods of Treatment Using Tevogen’s Investigational CTL Therapy for COVID-19

Businesswire – December 8th, 2021


Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council

Businesswire – December 6th, 2021


SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19

Yale School of Public Health – December 6th, 2021


Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Businesswire – December 2nd, 2021


FDA OK’s next phase for Jefferson University’s new COVID-19 treatment

6ABC News – November 29th, 2021


SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced

Yale School of Public Health – November 22nd, 2021


Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients

Businesswire – November 16th, 2021


Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council

Businesswire – October 27th, 2021


A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System

Yale School of Public Health – October 8th, 2021


Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy

Businesswire – September 9th, 2021


Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

Businesswire – September 1st, 2021


Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model

Pharma Tech Outlook – August 30th, 2021


Tevogen Bio Partners with Yale School of Public Health to Prepare Tomorrow’s Leaders in Regulatory Science

Businesswire – July 14th, 2021


Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Businesswire – July 12th, 2021


Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Businesswire – May 11th, 2021


Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Businesswire – April 12th, 2021


Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.

Cell & Gene – March 23rd, 2021


Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Businesswire – March 15th, 2021


Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Newswire – January 25th, 2021


Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

Newswire – October 14th, 2020


Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.

6ABC – August 20th, 2020


Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza

Newswire – August 10th, 2020


Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Newswire – July 15th, 2020

Tevogen Corporate Office – Warren, New Jersey

Presenting the Future Research and Manufacturing Facility of Tevogen Bio

Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly research and manufacturing facility to accommodate its anticipated growth. This planned facility will serve as the company’s central hub for research, manufacturing, and distribution. Congratulations to our team of visionary architects and lab engineers!

Social Media

© 2021 Tevogen Bio. All Rights Reserved.